Site Identification Tool
The US-based pharmaceutical company wanted to understand the course of rare genetic disorders that affect the brain. The study was to gain a better understanding of the progression of the disease being studied and the effect of interventions. Previously, only 45% of the identified sites were able to recruit close to the projected patient volumes. The company therefore had trial costs crossing the stipulated budgets significantly owing to higher cycle times, and projected enrolment rates not being hit.
Stay up to date with the latest marketing, sales, and service tips and news.
Subscribe to our newsletter to receive latest updates